深度测序鉴定慢性乙型肝炎患者的乙型肝炎病毒核心蛋白特

StephenW

Antiviral Res. 2018 Aug 16. pii: S0166-3542(18)30014-7. doi: 10.1016/j.antiviral.2018.08.009. [Epub ahead of print]
Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients.
van der Ree MH1, Jansen L1, Welkers MRA2, Reesink HW1, Feenstra KA3, Kootstra NA4.
Author information

1
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
2
    Department of Medical Microbiology, Academic Medical Center, Amsterdam, The Netherlands.
3
    Center for Integrative Bioinformatics VU (IBIVU), Department of Computer Science, Amsterdam Institute for Molecules, Medicine and Systems (AIMMS), VU University Amsterdam, The Netherlands.
4
    Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: [email protected].

Abstract
BACKGROUND:

We aimed to identify HBc amino acid differences between subgroups of chronic hepatitis B (CHB) patients.
METHODS:

Deep sequencing of HBc was performed in samples of 89 CHB patients (42 HBeAg positive, 47 HBeAg negative). Amino acid types were compared using Sequence Harmony to identify subgroup specific sites between HBeAg-positive and -negative patients, and between patients with combined response and non-response to peginterferon/adefovir combination therapy.
RESULTS:

We identified 54 positions in HBc where the frequency of appearing amino acids was significantly different between HBeAg-positive and -negative patients. In HBeAg negative patients, 22 positions in HBc were identified which differed between patients with treatment response and those with non-response. The fraction non-consensus sequence on selected positions was significantly higher in HBeAg-negative patients, and was negatively correlated with HBV DNA and HBsAg levels.
CONCLUSIONS:

Sequence Harmony identified a number of amino acid changes associated with HBeAg-status and response to peginterferon/adefovir combination therapy.

Copyright © 2018. Published by Elsevier B.V.
KEYWORDS:

Chronic hepatitis B; Deep sequencing; HBeAg status; Hepatitis B virus core protein; Treatment response

PMID:
    30121196
DOI:
    10.1016/j.antiviral.2018.08.009

StephenW

抗病毒药物2018年8月16日.pii：S0166-3542（18）30014-7。 doi：10.1016 / j.antiviral.2018.08.009。 [提前打印]
深度测序鉴定慢性乙型肝炎患者的乙型肝炎病毒核心蛋白特征。
van der Ree MH1，Jansen L1，Welkers MRA2，Reesink HW1，Feenstra KA3，Kootstra NA4。
作者信息

1
    荷兰阿姆斯特丹学术医学中心胃肠病学和肝病学系;荷兰阿姆斯特丹学术医学中心实验免疫学系。
2
    荷兰阿姆斯特丹学术医学中心医学微生物学系。
3
    阿姆斯特丹荷兰阿姆斯特丹大学分子，医学和系统研究所（AIMMS）计算机科学系综合生物信息学中心（IBIVU）。
4
    荷兰阿姆斯特丹学术医学中心实验免疫学系。电子地址：[email protected]。

抽象
背景：

我们的目的是确定慢性乙型肝炎（CHB）患者亚组之间的HBc氨基酸差异。
方法：

在89例CHB患者的样本中进行了HBc的深度测序（42例HBeAg阳性，47例HBeAg阴性）。使用Sequence Harmony比较氨基酸类型以鉴定HBeAg阳性和阴性患者之间的亚组特异性位点，以及具有联合应答和对聚乙二醇干扰素/阿德福韦联合治疗无应答的患者之间。
结果：

我们在HBc中鉴定了54个位置，其中出现的氨基酸频率在HBeAg阳性和阴性患者之间显着不同。在HBeAg阴性患者中，确定了HBc中的22个位置，其在治疗反应患者和无反应患者之间存在差异。 HBeAg阴性患者中所选位置的非共有序列分数显着较高，并且与HBV DNA和HBsAg水平呈负相关。
结论：

Sequence Harmony鉴定了许多与HBeAg状态相关的氨基酸变化以及对聚乙二醇干扰素/阿德福韦联合治疗的反应。

版权所有©2018。Elsevier B.V.
关键词：

慢性乙型肝炎;深度排序; HBeAg状态;乙型肝炎病毒核心蛋白;治疗反应

结论：
    30121196
DOI：
    10.1016 / j.antiviral.2018.08.009